New Stock News | FangTuo Bio

According to a disclosure by the Hong Kong Stock Exchange on August 28, Frontera Therapeutics (abbreviated as: ) submitted a listing application to the main board of the Hong Kong Stock Exchange, with UBS Group and HAITONG INT'L as its joint sponsors. The prospectus indicates that Frontera Therapeutics is a clinical-stage gene therapy company dedicated to the independent development of recombinant adeno-associated virus (rAAV) gene therapies. The company's pipeline particularly focuses on ophthalmic and cardiovascular diseases. The company has established the rAAV gene therapy R&D platform (EXACTE) to screen candidate drugs with better tissue tropism, high transduction efficiency, long-term efficacy, and excellent safety.